Found: 24
Select item for more details and to access through your institution.
A Neurofunctional Domains Approach to Evaluate D1/D5 Dopamine Receptor Partial Agonism on Cognition and Motivation in Healthy Volunteers With Low Working Memory Capacity.
- Published in:
- International Journal of Neuropsychopharmacology, 2020, v. 23, n. 5, p. 287, doi. 10.1093/ijnp/pyaa007
- By:
- Publication type:
- Article
LOW PREVALENCE OF AMYLOID POSITIVITY IN HEALTHY ELDERLY PARTICIPANTS OF A METHODOLOGY STUDY EVALUATING REMOTE TABLET-BASED COGNITIVE LEARNING.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, p. P1062, doi. 10.1016/j.jalz.2016.06.2219
- By:
- Publication type:
- Article
A randomized, double-blind, sponsor-unblinded, placebo- and positive-controlled study to evaluate the effects of single oral administrations of PF-04995274 on scopolamine-induced deficits in cognitive function in healthy adults
- Published in:
- 2012
- By:
- Publication type:
- Abstract
Systems pharmacology modeling in 5HT4: Prediction and outcome of a clinical scopolamine impairment trial and further application to Alzheimer's disease pathology
- Published in:
- 2012
- By:
- Publication type:
- Abstract
Modulation of soluble APPα in brain by PF-04995274, a 5HT<sub>4</sub> partial agonist, following single oral doses in healthy human volunteers: Study design and PK-PD analysis
- Published in:
- 2012
- By:
- Publication type:
- Abstract
An updated Aβ systems kinetic model for mouse, monkey and human
- Published in:
- 2012
- By:
- Publication type:
- Abstract
Beta-amyloid aggregation human systems pharmacology modeling: Development and application to pharmacological targets in Alzheimer's disease
- Published in:
- 2012
- By:
- Publication type:
- Abstract
Pharmacokinetics, safety and tolerability of PF-04995274: A 5HT4 partial agonist being developed for the treatment of Alzheimer's disease
- Published in:
- 2011
- By:
- Publication type:
- Abstract
Translational receptor occupancy for the 5-HT4 partial agonist PF-04995274 in rats, non-human primates and healthy volunteers
- Published in:
- 2011
- By:
- Publication type:
- Abstract
Evaluation of D<sub>1</sub>/D<sub>5</sub> Partial Agonist PF-06412562 in Parkinson's Disease following Oral Administration.
- Published in:
- Neurodegenerative Diseases, 2018, v. 18, n. 5/6, p. 262, doi. 10.1159/000492498
- By:
- Publication type:
- Article
Dopamine D 1 Agonists: First Potential Treatment for Late-Stage Parkinson's Disease.
- Published in:
- Biomolecules (2218-273X), 2023, v. 13, n. 5, p. 829, doi. 10.3390/biom13050829
- By:
- Publication type:
- Article
PET imaging of M4 muscarinic acetylcholine receptors in rhesus macaques using [ 11 C]MK-6884: Quantification with kinetic modeling and receptor occupancy by CVL-231 (emraclidine), a novel positive allosteric modulator.
- Published in:
- Journal of Cerebral Blood Flow & Metabolism, 2024, v. 44, n. 8, p. 1329, doi. 10.1177/0271678X241238820
- By:
- Publication type:
- Article
Parkinson disease among patients treated for benign prostatic hyperplasia with α1 adrenergic receptor antagonists.
- Published in:
- 2021
- By:
- Publication type:
- journal article
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson’s Disease.
- Published in:
- Clinical Drug Investigation, 2018, v. 38, n. 6, p. 509, doi. 10.1007/s40261-018-0632-6
- By:
- Publication type:
- Article
First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease.
- Published in:
- Alzheimer's Research & Therapy, 2016, v. 8, p. 1, doi. 10.1186/s13195-016-0177-y
- By:
- Publication type:
- Article
Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 4, p. 796, doi. 10.1002/cpt.1782
- By:
- Publication type:
- Article
Studying the Progression of Amyloid Pathology and Its Therapy Using Translational Longitudinal Model of Accumulation and Distribution of Amyloid Beta.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2017, v. 6, n. 10, p. 676, doi. 10.1002/psp4.12249
- By:
- Publication type:
- Article
Impact of Phase 1 study design on estimation of QT interval prolongation risk using exposure–response analysis.
- Published in:
- Journal of Pharmacokinetics & Pharmacodynamics, 2019, v. 46, n. 6, p. 605, doi. 10.1007/s10928-019-09661-4
- By:
- Publication type:
- Article
PF-06649751 efficacy and safety in early Parkinson's disease: a randomized, placebo-controlled trial.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2020, v. 13, p. 1, doi. 10.1177/1756286420911296
- By:
- Publication type:
- Article
PF-06649751 efficacy and safety in early Parkinson’s disease: a randomized, placebo-controlled trial.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2020, v. 13, p. 1, doi. 10.1177/1756286420911296
- By:
- Publication type:
- Article
Phase 1 Parkinson's Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated.
- Published in:
- Neurology & Therapy, 2018, v. 7, n. 2, p. 307, doi. 10.1007/s40120-018-0114-z
- By:
- Publication type:
- Article
In Vitro Transport and Partitioning of AL-4940, Active Metabolite of Angiostatic Agent Anecortave Acetate, in Ocular Tissues of the Posterior Segment.
- Published in:
- Journal of Ocular Pharmacology & Therapeutics, 2010, v. 26, n. 2, p. 137, doi. 10.1089/jop.2009.0132
- By:
- Publication type:
- Article
Controlled Delivery of Ganciclovir to the Retina with Drug-Loaded Poly(D,L-lactide-co-glycolide) (PLGA) Microspheres Dispersed in PLGA-PEG-PLGA Gel: A Novel Intravitreal Delivery System for the Treatment of Cytomegalovirus Retinitis.
- Published in:
- Journal of Ocular Pharmacology & Therapeutics, 2007, v. 23, n. 3, p. 264, doi. 10.1089/jop.2006.132
- By:
- Publication type:
- Article
A novel approach to evaluate the pharmacodynamics of a selective dopamine D1/D5 receptor partial agonist (PF-06412562) in patients with stable schizophrenia.
- Published in:
- 2019
- By:
- Publication type:
- journal article